Shareholder Alert: The Ademi Firm investigates whether HilleVax, Inc. is obtaining a Fair Price for its Public Shareholders

Core Viewpoint - The Ademi Firm is investigating HilleVax for potential breaches of fiduciary duty and other legal violations related to its transaction with XOMA Royalty Corporation [1] Transaction Details - HilleVax shareholders will receive $1.95 per share in cash along with contingent value rights (CVR) that may provide additional payments based on HilleVax's remaining cash above $102.95 million, savings from Boston office lease obligations, and proceeds from the sale of the company's norovirus vaccine programs within specified timeframes [2] - HilleVax insiders are set to receive substantial benefits as part of the change of control arrangements [2] Investigation Focus - The transaction agreement imposes significant penalties on HilleVax for accepting competing bids, which may limit competing transactions unreasonably [3] - The investigation is centered on the conduct of HilleVax's board of directors and whether they are fulfilling their fiduciary duties to all shareholders [3]